Viral pathogenesis and anti-viral strategies
At our laboratory, we are deeply immersed in the ongoing battle against infectious diseases, particularly focusing on viruses that pose substantial threats to public health in India. DENV and JEV have emerged as two of the most common names, possessing significant challenges demanding our dedicated attention.
​
The DENV Chapter
Dengue, caused by any of the four Dengue virus serotypes (1-4), stands as a significant public health concern, notably evident in extensive outbreaks during the summer of 2023 in Central American countries and the Caribbean. The economic burden of Dengue is substantial, estimated at 750 billion Indian rupees, with India bearing a significant portion of 91.2 billion of it. Currently, the absence of effective antiviral medicines or vaccines poses the risk of DENV infection and the severity of dengue disease illness. Johnson & Johnson (JNJ) is actively working on a dengue drug candidate, JNJ-1802, a small molecule oral drug formulation that is currently under clinical phase II against DENV-3 mild infection.
At present, our focus lies on the development of small molecule(s) as anti-DENV therapeutic and to design neutralizing monoclonal antibodies as the therapeutics against the disease. The prime focus of developing these antibodies is to achieve higher neutralizing efficacy while avoiding the Antibody Dependent Enhancement (ADE). These therapeutics are currently being approached using a non-classical methodology involving bioinformatics and Insilco development.
​
The JEV Chapter
Japanese Encephalitis, a significant threat in various Indian regions, demands our focused attention. Studying JEV in the Indian context becomes a proactive measure to prevent and manage future outbreaks effectively. With this, our group is actively working on the development of therapeutic agents as well as Virus-Like Particles (VLPs)-based vaccine candidates against JEV infection. By working on the therapeutics as well as the vaccine development, we contribute to prevention as well as treatment of the disease.
​​​​
​
​
​
In conclusion, our research endeavours go beyond academic pursuits; they represent a strategic investment in public health. The emphasis on developing therapeutics, including innovative subunit vaccines, showcases our commitment to addressing the nation's unique health challenges. Through these endeavours, our scientific community not only contributes to global knowledge but, more importantly, enhances the tangible well-being of the Indian population.
Still curious to know more? Drop us an email (rahul.shukla1[at]cdri[dot]res[dot]in)